SUO 2024 Bladder Cancer

Viewing 1-20 of 47 articles

SUO 2024: Sexual Dysfunction and Radical Cystectomy

SUO 2024: Emerging Therapeutics: Combination Therapy in Neoadjuvant Setting

SUO 2024: Preventing and Managing Long Term Complications of Radical Cystectomy

SUO 2024: Exploratory Analysis of Post-treatment Outcomes in Patients with Bacillus Calmette-Guerin-unresponsive High-risk, Non-muscle Invasive Bladder Cancer Who Experienced Non-Response to Pembrolizumab Monotherapy in KEYNOTE-057

SUO 2024: Setting the Stage: Our Current Options for BCG Unresponsive NMIBC

SUO 2024: CORE-008: A Phase 2, Multi-Arm, Multi-Cohort, Open-Label Study to Evaluate the Safety and Efficacy of Cretostimogene Grenadenorepvec in Participants with High-Risk NMIBC

SUO 2024: Genitourinary Cancer Care among Geriatric Patients

SUO 2024: Access to Care for Resource Challenged Populations: Tele-Cystoscopy

SUO 2024: The Cretostimogene Grenadenorepvec Expanded Access Program in Patients with NMIBC Unresponsive to BCG

SUO 2024: Multicenter Experience with First-Line Intravesical Gemcitabine-Docetaxel Versus Bacillus Calmette-Guerin for High-Risk NMIBC

SUO 2024: An Artificial Intelligence Powered Model to Predict Response to Intravesical BCG Versus Gemcitabine-Docetaxel for High Risk NMIBC

SUO 2024: Co-formulated Vibostolimab/pembrolizumab or Co-formulated Favezelimab/pembrolizumab for Bacillus Calmette-Guerin-unresponsive High-risk Non-muscle Invasive Bladder Cancer: Cohort C of Phase II KEYNOTE-057 Trial

SUO 2024: A Phase I Dose-Escalation Study of UGN-301 (Zalifrelimab) as Monotherapy and in Combination with Other Agents in Patients with Recurrent Non-muscle Invasive Bladder Cancer

SUO 2024: ADVANCED-2: Phase 2 Open-Label Study to Evaluate Safety and Anti-Tumor Activity of Intravesical Instillation of TARA-002 in Adults with High-Grade Non-Muscle Invasive Bladder Cancer

SUO 2024: The Impact of BCG Shortage on Disease Recurrence for Patients with Non-Muscle Invasive Bladder Cancer: A SEER Patterns of Care Analysis.

SUO 2024: Moonrise-1: Phase 3 Study of TAR-210, an Erdafitinib Intravesical Targeted Releasing System, Versus Intravesical Chemotherapy in Patients with FGFR-Altered Intermediate Risk Non Muscle Invasive Bladder Cancer

SUO 2024: Initial Results of a Multicenter Phase II trial of Intravesical Gemcitabine plus BCG for Patients with BCG-exposed Non-muscle Invasive Bladder Cancer

SUO 2024: Urine Tumor DNA Analysis in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC) Patients Treated with Durvalumab Containing Regimens in the HCRN GU16-243: ADAPT-BLADDER Trial.

SUO 2024: Utility of Rescue Bacillus Calmette-Guerin Therapy in Treatment of BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer

SUO 2024: Home Instillation of UGN-102 for Primary Chemoablation of Recurrent Low-Grade Intermediate Risk NMIBC: A Single Arm, Open Label, Phase 3B Trial

1
2
3